



Physiomics Plc  
The Magdalen Centre  
The Oxford Science Park  
Robert Robinson Avenue  
Oxford  
OX4 4GA  
UK

3<sup>rd</sup> January 2019

Physiomics plc

("Physiomics") or ("the Company")

### Strategic collaboration

*Physiomics signs collaboration agreement with Medicines Discovery Catapult*

[Physiomics plc](#) (AIM: PYC), is pleased to announce that it has entered into a strategic collaboration with the [Medicines Discovery Catapult](#). Physiomics will be part of the "Virtual R&D" network of advisors and available to provide advice to the many small biotechnology companies supported by Medicines Discovery Catapult.

Physiomics offers a range of services including its proprietary Virtual Tumour technology to predict the effect of oncology drugs and improve the success rate of oncology R&D. It works with companies ranging from start-ups to some of the world's largest pharmaceutical companies and has experience in a wide range of treatments, including radiation, DNA damage/ repair agents and immune therapies.

Dr Jim Millen, CEO said: "We are delighted to be working with Medicines Discovery Catapult; an organisation that plays such a key role in supporting emerging biotech companies in the UK. We're also excited by the potential that this new relationship offers to connect Physiomics to emerging players in the field of oncology."

Enquiries:

**Physiomics plc**  
Dr Jim Millen, CEO  
+44 (0)1865 784 980

**WH Ireland Limited (nomad)**  
Katy Mitchell  
+44 (0) 161 832 2174

**Hybridan LLP (broker)**  
Claire Louise Noyce  
+44 (0) 203 764 2341

## **Notes to Editor**

### **About Physiomics**

Physiomics plc (AIM: PYC) is a solutions provider to the R&D based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by over 60 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

### **About the Medicines Discovery Catapult**

Medicines Discovery Catapult is a national facility connecting the UK community to accelerate innovative drug discovery. It provides unique scientific capabilities and acts as a gateway to UK resources and expertise, supporting UK SMEs to drive the development and industrialisation of new approaches for the discovery of new medicines.

By validating new ways of discovering medicines and driving key talent and expertise across the sector, it supports the UK life sciences industry, SMEs and innovators to deliver growth for the UK economy. Ultimately, new industrialised technologies are vital for delivering new medicines to patients, faster.

Its Virtual R&D platform accesses a unique national network of up-to-date industry-skilled consultants and service providers to deliver value to biotech, academia, charities and venture capital through: rapid, independent due diligence of programmes throughout the R&D value chain; the creation of agile, industry-relevant, R&D project plans and achievable IP estates; and efficient management of multiple R&D delivery partners across portfolios of projects in order to provide best practice in modern medicines R&D processes.